Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
7920 participants
INTERVENTIONAL
2026-03-01
2027-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)
NCT05989802
Evaluation of Four Stool Processing Methods Combined With Xpert MTB/RIF Ultra for Diagnosis of Intrathoracic Paediatric TB (TB-Speed - Stool Processing)
NCT04203628
Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19
NCT05220163
Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals
NCT03042754
Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)
NCT01331811
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To overcome some of these barriers, health systems often require referral of children with signs, symptoms, or screening investigations consistent with TB ("presumptive TB") to secondary or tertiary health centres so that expert staff can be consulted, and relevant specimens, or further specimens, taken. This may result in additional cost for both the child and their family and the health system, cause further delays in diagnosis and treatment initiation, and may ultimately result in greater morbidity and mortality.
To reduce the case detection gap and to avoid diagnostic delays, policymakers and programme implementers have promoted child and adolescent TB assessment at primary healthcare (PHC) or child health centres, often through integration into existing child services diagnosing similar conditions. While child TB case notifications prior to the COVID-19 pandemic had been increasing, they declined sharply between 2019 and 2020 due to COVID. Childhood notifications recovered more slowly compared to adults in 2021, and efforts continue to be hampered by limited PHC staff expertise, poor access to diagnostic tests including chest X-ray, and a lack of dedicated time for over-burdened health care staff.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic
Diagnostic Test - all participants
Xpert MTB/RIF Ultra
automated molecular test
Truenat, MTB
Micro-Polymerase Chain Reaction (PCR) diagnostic test
Truenat MTB Plus
Micro-Polymerase Chain Reaction (PCR) diagnostic test
TB LAMP
manual molecular test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xpert MTB/RIF Ultra
automated molecular test
Truenat, MTB
Micro-Polymerase Chain Reaction (PCR) diagnostic test
Truenat MTB Plus
Micro-Polymerase Chain Reaction (PCR) diagnostic test
TB LAMP
manual molecular test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fulfils the criteria of presumptive TB according to the definition 10.1 of the protocol, or TB associated risk factors according to the definition 10.2. of the protocol
3. Diagnosed with TB disease
Exclusion Criteria
2. Parent or guardian does not allow the child to participate in the study or declines to sign the ICF.
3. The child does not wish to participate in the study or declines to sign the Assent Form (where applicable)
0 Years
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre for Control of Chronic Disease (CCCD),icddr,b
UNKNOWN
Comité National d'Ethique pour la Recherche en Santé Humaine
UNKNOWN
KEMRI-Wellcome Trust Collaborative Research Program
OTHER
National Lung Hospital, Vietnam
UNKNOWN
Liverpool School of Tropical Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.